Latest news with #drug
Yahoo
a day ago
- Health
- Yahoo
Made in Singapore cancer drug could help cure blindness, trial in country to start soon
SINGAPORE, July 14 — A drug developed for the treatment of cancer has showed promise in treating blindness. According to The Singapore Times, the drug PRL3-zumab was developed by the A*Star Institute of Molecular and Cell Biology (IMCB) and was created as a broad-spectrum anti-cancer drug that could treat not one but multiple types of cancer. In a Singapore trial of the drug, patients with either wet age-related macular degeneration (AMD) or diabetic retinopathy will receive a shot of the medicine intravenously. Globally, these two conditions are among the most common causes of loss of sight. How does it work? According to pre-clinical studies published in Nature Communications as PRL3-zumab reduced leakage from damaged blood vessels. Currently both Wet AMD and diabetic retinopathy are treated with periodic injections into the sclera or white part of the eye periodically to reduce leakage and abnormal growth in blood vessels. The intravenous method, according to the studies, led to an 86 per cent greater reduction in blood vessel leakage compared to injections. After being granted approval by Singapore's Health Sciences Authority on June 16, a safety trial is set to begin by late 2025 with more human trials following to test the drug's efficacy.
Bloomberg
3 days ago
- Health
- Bloomberg
Roche Suffers Setback as Lung Drug Gets Mixed Result in Trial
Roche Holding AG 's experimental drug for a deadly lung condition got mixed results in trials, a setback as the company seeks to accelerate the development of new treatments. The late-stage trials for astegolimab — the medicine being developed to treat chronic obstructive pulmonary disease, or COPD — offered contrasting results, according to a statement on Monday.
Yahoo
3 days ago
- Health
- Yahoo
Missing A Tooth? Scientists Develop New Drug that Regrows Teeth
If you're one of the millions of people who have a gaping space in your gums where a tooth used to be, there's reason to hope you might not have to spend the rest of your days with an uneven smile or fake teeth. Scientists in Japan have announced that they are moving forward with a drug that is capable of regrowing human teeth, Popular Mechanics reports. The drug works by suppressing an antibody called uterine sensitization–associated gene-1 (USAG-1). In ferrets and mice, this protein is shown to inhibit the growth of teeth, according to Dentistry Today. In a press release, Dr. Katsu Takahashi, a lead author of a study from Kyoto University and the University of Fukui, said, "We knew that suppressing USAG-1 benefits tooth growth. What we did not know was whether it would be enough.' He adds, "Ferrets are diphyodont animals with similar dental patterns to humans.' An article from Dentistry Today reports that researchers found that the 'USAG-1 protein could limit the growth of teeth in mice.' And that suppressing the protein would 'potentially invite their teeth to grow.' Trials conducted on mice were successful. Even more exciting, Dentistry Today reports, is that Takahashi's previous research shows that humans have a third row of teeth in their mouths. Those teeth are available as buds, and Takahashi believes they can be activated. The human trial for regrowing teeth is expected to last about 11 months, according to Popular Mechanics. Originally, it will consist of 30 men between the ages of 30 and 64. A qualification is that they each must be missing a tooth, an article in New Atlas reports. The article also states that if the trial is proven safe and effective, plans are to open the trial to patients between the ages of 2 to 7, who are missing at least four teeth. Researchers hope to have the drug available by the year 2030, Popular Mechanics A Tooth? Scientists Develop New Drug that Regrows Teeth first appeared on Men's Journal on Jul 20, 2025 Solve the daily Crossword
Reuters
5 days ago
- Health
- Reuters
US FDA advisers vote against Otsuka's PTSD combination treatment
July 18 (Reuters) - The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's (4578.T), opens new tab drug when used in combination with Viatris' (VTRS.O), opens new tab Zoloft for the treatment of adults with PTSD. The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft for treating the condition. PTSD, a disorder caused by very stressful events, affects about 4% of U.S. adults and is commonly associated with war veterans. But natural disasters, abuse or other trauma may also trigger the condition in civilians. The recommendation comes after the FDA's staff reviewers on Wednesday raised efficacy concerns over the use of the combination therapy, citing inconsistent trial results and a modest treatment effect.
Yahoo
5 days ago
- Health
- Yahoo
US FDA advisers vote against Otsuka's PTSD combination treatment
(Reuters) -The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's drug when used in combination with Viatris' Zoloft for the treatment of adults with PTSD. The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination with Zoloft for treating the condition. PTSD, a disorder caused by very stressful events, affects about 4% of U.S. adults and is commonly associated with war veterans. But natural disasters, abuse or other trauma may also trigger the condition in civilians. The recommendation comes after the FDA's staff reviewers on Wednesday raised efficacy concerns over the use of the combination therapy, citing inconsistent trial results and a modest treatment effect. Solve the daily Crossword
